Our meta-analysis demonstrated that CD3+, CD4+, CD4+CD8+, CD3+CD56+ and NK cells were increased after DC-CIK treatment, therefore suggesting the improvement of immune function after immunotherapy in the NSCLC patients. This evidence concerns the gene NCAM1 and non-small cell lung carcinoma.